UNSPSC 51182708: Metformin/saxagliptin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS502. This VA Drug Class (HS502) classifies this compound as belonging to the group ORAL HYPOGLYCEMIC AGENTS, ORAL.

UNSPSC 51182708 Metformin/saxagliptin is a Commodity code that tracks procurement of specific pharmaceutical products, but the recent state and local opportunities posted under this code do not align with its nominal scope. Seminole County, Florida solicited naloxone and drug deactivation systems through IFB 60459723LAS in June 2026, and the Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription fulfillment capabilities—neither of which involves metformin or saxagliptin products. The mismatch suggests that state and local procurement offices may be using this code as a catchall for pharmaceutical and pharmacy-related purchases rather than as a strict product-line classifier. Issuing bodies tagging activity under this code include county health departments and state HHS agencies, though the recent-opportunities block shows limited volume relative to the code's nominal product scope.

Geographic activity is concentrated in Florida and Texas based on the two recent opportunities. Seminole County's naloxone procurement (IFB 60459723LAS, due July 26, 2023) calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, on a fixed-fee basis with an initial two-year term and one-year renewal option. The Texas HHS Commission's RFI (HHS0017013, response deadline April 3, 2026) sought vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, targeting vendors with experience negotiating net-pricing models for self-insured employers and government health plans. The code shows sparse recent activity overall, and procurement under it appears driven by exploratory or episodic health-system needs rather than sustained commodity demand.